Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mahant, N.
Right arrow Articles by Graham, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mahant, N.
Right arrow Articles by Graham, S.
Related Collections
Right arrow All Movement Disorders
Right arrow Huntington's disease
Right arrow Clinical trials Methodology/study design
NEUROLOGY 2003;61:1085-1092
© 2003 American Academy of Neurology

Huntington’s disease

Clinical correlates of disability and progression

N. Mahant, MBBS FRACP, E.A. McCusker, MBBS (Hons), FRACP, K. Byth, PhD and S. Graham, BSc The Huntington Study Group*

From the Department of Neurology (Drs. Mahant and McCusker, and S. Graham) and Westmead Millennium Institute (Dr. Byth), Westmead Hospital; and University of Sydney (Dr. Mahant), NSW, Australia.

Address correspondence and reprint requests to Dr. E.A. McCusker, Director, Huntington Disease Service, Department of Neurology, Westmead Hospital, Westmead, NSW 2145, Australia; e-mail: elizabeth_mccusker{at}mail.wmi.usyd.edu.au

Objective: To define the phenotypic variation in a large population of patients with Huntington disease (HD) and to identity clinical features that predict disability and the rate of disease progression.

Methods: The authors analyzed data on 1,026 patients, followed for a median of 2.7 years, using a mixed effects model. The factors studied included the age at onset, the major clinical feature at onset, the severity of motor and cognitive impairment, and the level of disability.

Results: The mean age at onset was 41.5 (range 8 to 83) years, and patients were enrolled at all stages of disease. Younger onset was associated with more dystonia, less chorea, and a faster rate of motor, cognitive, and functional progression. The rate of progression was not related to the major clinical feature at onset or the sex of the affected parent. Disability correlated with the motor score (excluding chorea and dystonia) and the symbol-digit modalities test. Weight loss correlated with severe chorea.

Conclusions: The rate of progression of HD was significantly more rapid with a younger age at onset. Therefore, CAG repeat length may be an important determinant of not only the age at onset, but also the rate of disease progression. Chorea was associated with weight loss, but chorea and dystonia were not major determinants of disability.


Received December 23, 2002. Accepted in final form June 17, 2003.

*Members of the Huntington Study Group are listed in the Appendix on page 1091.




This article has been cited by other articles:


Home page
BrainHome page
K. Suzuki, M. Katsuno, H. Banno, Y. Takeuchi, N. Atsuta, M. Ito, H. Watanabe, F. Yamashita, N. Hori, T. Nakamura, et al.
CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA
Brain, January 1, 2008; 131(1): 229 - 239.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
K. Wojaczynska-Stanek, D. Adamek, E. Marszal, and D. Hoffman-Zacharska
Huntington Disease in a 9-Year-Old Boy: Clinical Course and Neuropathologic Examination
J Child Neurol, December 1, 2006; 21(12): 1068 - 1073.
[Abstract] [PDF]


Home page
NeurologyHome page
A. Rosenblatt, K. -Y. Liang, H. Zhou, M. H. Abbott, L. M. Gourley, R. L. Margolis, J. Brandt, and C. A. Ross
The association of CAG repeat length with clinical progression in Huntington disease
Neurology, April 11, 2006; 66(7): 1016 - 1020.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
B. K. Puri, B. R. Leavitt, M. R. Hayden, C. A. Ross, A. Rosenblatt, J. T. Greenamyre, S. Hersch, K. S. Vaddadi, A. Sword, D. F. Horrobin, et al.
Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial
Neurology, July 26, 2005; 65(2): 286 - 292.
[Abstract] [Full Text] [PDF]


Home page
BiostatisticsHome page
K. Byth and D. R. Cox
On the relation between initial value and slope
Biostat., July 1, 2005; 6(3): 395 - 403.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.